Taysha Gene Therapies, Inc. (TSHA) financials: revenue, earnings and cash flow
Fiscal 2020–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Net income in fiscal 2025 was -$109M, a net margin of -1115.3%; the best year in this period was 2020 with -$60M.
Over the twelve months to September 30, 2026, revenue was $5M and net income -$156M.
Free cash flow was -$94M in fiscal 2025 and positive in 0 of the 6 years shown.
The diluted share count rose 1710% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Revenue | $5M | $10M | $8M | $15M | $3M | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Operating income | -$161M | -$110M | -$91M | -$72M | -$162M | -$173M | -$43M |
| Net income | -$156M | -$109M | -$89M | -$112M | -$166M | -$175M | -$60M |
| EPS (diluted) | $-0.43 | $-0.34 | $-0.36 | $-0.96 | $-3.78 | $-4.64 | $-3.40 |
| R&D | $126M | $86M | $66M | $57M | $91M | $132M | $32M |
| Revenue growth | — | +17.3% | −46.1% | +517.6% | — | — | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$141M | -$93M | -$81M | -$73M | -$88M | -$117M | -$31M |
| Capital spending | -$716000 | -$738000 | -$374000 | -$4M | -$21M | -$15M | -$82000 |
| Free cash flow | -$142M | -$94M | -$82M | -$77M | -$109M | -$132M | -$31M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | — | — | — |
| Stock-based pay | $21M | $13M | $13M | $8M | $18M | $18M | $3M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Cash | — | $320M | $139M | $144M | $88M | $149M | $251M |
| Debt | — | $70M | $63M | $61M | $60M | $37M | — |
| Equity | — | $247M | $72M | $75M | $949000 | $95M | $251M |
| Total assets | — | $343M | $160M | $173M | $126M | $214M | $259M |
| Shares (diluted) | 406M | 320M | 250M | 116M | 44M | 38M | 18M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — |
| Operating margin | -2935.4% | -1130.7% | -1097.5% | -468.8% | -6492.7% | — | — |
| Net margin | -2844.6% | -1115.3% | -1071.6% | -722.1% | -6635.3% | — | — |
| FCF margin | -2582.6% | -960.1% | -979.2% | -497.6% | -4356.9% | — | — |
| ROIC | — | -27.6% | -53.8% | -42.2% | -211.9% | -103.2% | -13.5% |
| ROE | — | -44.1% | -124.8% | -148.9% | -17493.6% | -183.0% | -23.9% |
Frequently asked questions
What is Taysha Gene Therapies’s annual revenue?
$10M in fiscal 2025 and $5M over the twelve months to September 30, 2026.
How much profit does Taysha Gene Therapies make?
Net income was -$109M in fiscal 2025 (net margin -1115.3%).
Is Taysha Gene Therapies’s revenue growing?
Yes: revenue rose 17.3% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.